These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 8237801

  • 1. Comparative effects of atenolol versus celiprolol on serum lipids and blood pressure in hyperlipidemic and hypertensive subjects.
    Dujovne CA, Eff J, Ferraro L, Goldstein RJ, Gotto AM, Hall WD, Harris WS, Held SJ, Herd A, Hunninghake DB.
    Am J Cardiol; 1993 Nov 15; 72(15):1131-6. PubMed ID: 8237801
    [Abstract] [Full Text] [Related]

  • 2. Effects of celiprolol vs. nifedipine on serum lipoproteins in patients with mild to moderate hypertension.
    Lijnen P, Van Hoof R, Amery A.
    Cardiovasc Drugs Ther; 1994 Jun 15; 8(3):509-13. PubMed ID: 7947368
    [Abstract] [Full Text] [Related]

  • 3. The effect of celiprolol on the blood lipid profile in hypertensive patients with high cholesterol levels.
    Fogari R, Zoppi A, Tettamanti F, Malamani G, Pasotti C.
    Cardiovasc Drugs Ther; 1991 Jan 15; 4 Suppl 6():1287-90. PubMed ID: 1826213
    [Abstract] [Full Text] [Related]

  • 4. The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension.
    Houston MC, Burger C, Hays JT, Nadeau J, Swift L, Bradley CA, Olafsson L.
    Am Heart J; 1990 Jul 15; 120(1):172-9. PubMed ID: 2193493
    [Abstract] [Full Text] [Related]

  • 5. A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.
    Milne RJ, Vander Hoorn S, Jackson RT.
    Pharmacoeconomics; 1997 Sep 15; 12(3):384-408. PubMed ID: 10170463
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the effect of celiprolol and nifedipine on blood pressure and plasma lipids.
    van Hoof R, Desager JP, Harvengt C, Fagard R, Lijnen P, Peerenboom P, Staessen J, Thijs L, Van Mieghem W, Amery A.
    J Cardiovasc Pharmacol; 1992 Aug 15; 20(2):268-73. PubMed ID: 1381018
    [Abstract] [Full Text] [Related]

  • 7. Quality of life before and during antihypertensive treatment: a comparative study of celiprolol and atenolol.
    Cleophas TJ, vd Mey N, Meulen J, Niemeyer MG.
    Am J Ther; 1997 Apr 15; 4(4):117-22. PubMed ID: 10423600
    [Abstract] [Full Text] [Related]

  • 8. Different hemodynamic effects of celipropol and atenolol in patients with mild to moderate hypertension.
    Saner H, Seiler A, Mahler F.
    Arzneimittelforschung; 1995 Jul 15; 45(7):790-5. PubMed ID: 8573224
    [Abstract] [Full Text] [Related]

  • 9. Lipid effects of celiprolol, a new cardioselective beta-blocker, versus propranolol.
    Sirtori CR, Johnson B, Vaccarino V, Montanari G, Cremoncini M, Gianfranceschi G, Sirtori M, Dujovne CA.
    Clin Pharmacol Ther; 1989 Jun 15; 45(6):617-26. PubMed ID: 2567218
    [Abstract] [Full Text] [Related]

  • 10. Quality of life before and during antihypertensive treatment: a comparative study of celiprolol and atenolol.
    Cleophas TJ, van der Mey N, van der Meulen J, Niemeyer MG.
    Int J Clin Pharmacol Ther; 1996 Jul 15; 34(7):312-7. PubMed ID: 8832309
    [Abstract] [Full Text] [Related]

  • 11. Effect of celiprolol and metoprolol on lipids, fibrinogen and airways function in hyperlipidaemic hypertensives: a randomised double-blind long-term parallel group trial.
    Johnston GD, Vyssoulis G, Feely J, Holden RD, Radley DR.
    J Hum Hypertens; 1995 Feb 15; 9(2):123-9. PubMed ID: 7752174
    [Abstract] [Full Text] [Related]

  • 12. A randomized double-blind study of atenolol and celiprolol in mild to moderate hypertension.
    Silke B, Rosenthal F, Taylor S.
    J Cardiovasc Pharmacol; 1986 Feb 15; 8 Suppl 4():S122-6. PubMed ID: 2427841
    [Abstract] [Full Text] [Related]

  • 13. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups.
    Pollare T, Lithell H, Mörlin C, Präntare H, Hvarfner A, Ljunghall S.
    J Hypertens; 1989 Jul 15; 7(7):551-9. PubMed ID: 2668407
    [Abstract] [Full Text] [Related]

  • 14. Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study.
    Rabkin SW, Huff MW, Newman C, Sim D, Carruthers SG.
    Hypertension; 1994 Aug 15; 24(2):241-8. PubMed ID: 8039850
    [Abstract] [Full Text] [Related]

  • 15. Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia.
    Fogari R, Zoppi A, Corradi L, Preti P, Mugellini A, Lusardi P.
    J Cardiovasc Pharmacol; 1999 Apr 15; 33(4):534-9. PubMed ID: 10218722
    [Abstract] [Full Text] [Related]

  • 16. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.
    Pollare T, Lithell H, Selinus I, Berne C.
    BMJ; 1989 Apr 29; 298(6681):1152-7. PubMed ID: 2500169
    [Abstract] [Full Text] [Related]

  • 17. Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men.
    Gordon NF, Scott CB, Duncan JJ.
    Am J Cardiol; 1997 Apr 15; 79(8):1065-9. PubMed ID: 9114765
    [Abstract] [Full Text] [Related]

  • 18. Effect of alpha- and selective beta-blockade for hypertension control on plasma lipoproteins, apoproteins, lipoprotein subclasses, and postprandial lipemia.
    Superko HR, Wood PD, Krauss RM.
    Am J Med; 1989 Jan 23; 86(1B):26-31. PubMed ID: 2913769
    [Abstract] [Full Text] [Related]

  • 19. [The effect of celiprolol hydrochloride for lipid metabolism--especially for the low density lipoprotein particle size].
    Totsuka M, Miyashita Y, Ito Y, Oyama T, Hashiguti S, Watanabe H, Shirai K, Ban T, Ishihara H, Yamamoto K, Kawano E, Mori J, Kanechi M.
    Nihon Ronen Igakkai Zasshi; 2001 May 23; 38(3):352-9. PubMed ID: 11431890
    [Abstract] [Full Text] [Related]

  • 20. Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis.
    Erley CM, Klass M, Krämer D, Berger E, Heyne N, Braun N, Wolf S, Risler T.
    Int J Clin Pharmacol Ther; 1996 Nov 23; 34(11):504-9. PubMed ID: 8937934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.